---
document_datetime: 2023-09-21 21:08:37
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kiovig-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: kiovig-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.074944
conversion_datetime: 2025-12-19 11:36:22.198483
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kiovig

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0117              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 24/06/2022                          |                                             | SmPC and PL                      |           |
| WS/2240              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 19/05/2022                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IA/0115/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 18/01/2022 | n/a | manufacturer of a |

<div style=\"page-break-after: always\"></div>

| IAIN/0114   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                       | 07/01/2022   | n/a        |                          |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------|
| T/0113      | Transfer of Marketing Authorisation                                                                                                                                                                                                                              | 19/11/2021   | 03/12/2021 |                          |
| WS/2060     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a medicinal product | 21/10/2021   | n/a        | biological/immunological |
| WS/2099     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   | 14/10/2021   | n/a        |                          |
| IAIN/0112   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes the properties of the FP                                 | 08/07/2021   | n/a        | do not affect            |
| WS/1964     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                    | 08/07/2021   | n/a        |                          |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                        |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/2047            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                             | 20/05/2021 | n/a |                                   |
| WS/1984            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size | 11/02/2021 | n/a |                                   |
| PSUSA/1633/ 202005 | Periodic Safety Update EU Single assessment - human normal immunoglobulin (IgG)                                                                                                                                                                                                                            | 14/01/2021 | n/a | PRAC Recommendation - maintenance |
| IA/0106/G          | This was an application for a group of variations. B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an                                                                                                                                                     | 08/12/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | already authorised B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised   |            |     | alternative method is   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------|
| WS/1924 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an protocol                                               | 26/11/2020 | n/a | approved                |
| WS/1882 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal is not related to a protocol                                                                | 17/09/2020 | n/a | product and             |

<div style=\"page-break-after: always\"></div>

| IAIN/0103   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                           | 20/08/2020   | n/a        |                                  |                   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------|
| IAIN/0101   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes properties of the FP                                             | 20/05/2020   | n/a        |                                  | do not affect the |
| IB/0099     | C.I.z - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                                                                                      | 11/05/2020   | 09/06/2020 | SmPC, Annex II, Labelling and PL | Veterinary        |
| II/0098     | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol | 17/04/2020   | n/a        |                                  |                   |
| WS/1524     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                     | 20/02/2020   | n/a        |                                  |                   |

<div style=\"page-break-after: always\"></div>

| IA/0097     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                               | 31/01/2020   | n/a        |                        |                   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------|
| T/0095      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                       | 02/10/2019   | 21/10/2019 | SmPC, Labelling and PL |                   |
| II/0091     | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH assessment is required                                                                                                                                                              | 05/09/2019   | n/a        |                        | where significant |
| IA/0094     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                             | 30/08/2019   | 21/10/2019 | Annex II and PL        |                   |
| N/0093      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                          | 17/07/2019   | 21/10/2019 | PL                     |                   |
| IAIN/0092/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - an updated/amended PMF when changes | 20/06/2019   | n/a        |                        | Inclusion of      |

<div style=\"page-break-after: always\"></div>

|           | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| WS/1519/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the | 14/06/2019 | n/a | medicinal product |
| WS/1500/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier product. (PMF 2nd step procedure) -                                                 | 16/05/2019 | n/a | of a medicinal    |

<div style=\"page-break-after: always\"></div>

|           | First-time inclusion of a new PMF NOT affecting the properties of the FP A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| WS/1494   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                    | 07/03/2019 | n/a        |             |
| IB/0088   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                          | 11/02/2019 | 05/03/2019 | SmPC and PL |
| IAIN/0085 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                          | 24/10/2018 | 05/03/2019 | SmPC        |
| WS/1407   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                              | 13/09/2018 | n/a        |             |
| IAIN/0082 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                     | 23/04/2018 | n/a        |             |

<div style=\"page-break-after: always\"></div>

|                    | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                              |            |            |                  |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----------------------------------|
| WS/1309            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products | 08/02/2018 | n/a        |                  |                                   |
| PSUSA/1633/ 201705 | Periodic Safety Update EU Single assessment - human normal immunoglobulin (IgG)                                                                                                                                                                                         | 11/01/2018 | n/a        |                  | PRAC Recommendation - maintenance |
| N/0079             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                        | 07/06/2017 | 05/03/2019 | PL               |                                   |
| IAIN/0077          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                          | 28/04/2017 | n/a        |                  |                                   |
| N/0078             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                        | 21/04/2017 | 05/03/2019 | Labelling and PL |                                   |
| WS/1085            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                           | 21/04/2017 | n/a        |                  |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                          |            |     |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/1633/ 201605 | Periodic Safety Update EU Single assessment - human normal immunoglobulin (IgG)                                                                                                                                                                                                                                                                                                                                      | 12/01/2017 | n/a | PRAC Recommendation - maintenance |
| WS/1003            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 15/12/2016 | n/a |                                   |
| WS/0966            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                           | 15/09/2016 | n/a |                                   |
| IAIN/0073          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                       | 27/07/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| WS/0882/G   | application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished variation                                                                                                                                       | 09/06/2016   | n/a        |                 | This was an product - Other   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------|
| IAIN/0071/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes affect the properties of the FP | 28/04/2016   | 02/06/2016 | Annex II and PL | do not                        |
| WS/0825     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                   | 14/01/2016   | n/a        |                 | B.I.a.2.b -                   |

<div style=\"page-break-after: always\"></div>

|                    | the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1633/ 201505 | Periodic Safety Update EU Single assessment - human normal immunoglobulin (IgG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/01/2016 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/0790            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier                                                                                                                                         | 19/11/2015 | 02/06/2016 | Annex II              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0065/G          | This was an application for a group of variations. Update of section 4.4 of the SmPC in order to include a new warning on possible false positive testing of assays used for diagnosis of fungal infections depending on detection of beta-D-glucans and to amend the existing warning on aseptic meningitis syndrome. Minor changes are made to the existing warnings on thromboembolic events and acute renal failure. The RMP is updated in relation to the new warning and to include the changes requested during the assessment of variation | 24/09/2015 | 02/06/2016 | SmPC, Annex II and PL | Based on new safety data the manufacturer proposes an update of the Product Information. The changes reflect the possibility of false positive readings in detection of ÃŸ-d- glucans for diagnosis of fungal infections, the higher incidence of aseptic meningitis syndrome (AMS) in female patients and its lack of dependency on dosage of administered immunoglobulin. They also make treating physicians more aware of thromboembolism and renal failure in patients requiring intravenous immunoglobulins. Due to new safety information with KIOVIG the list of adverse events has been updated. |

<div style=\"page-break-after: always\"></div>

|         | Update of section 4.8 of the SmPC in order to revise the frequency and MedRA SOC categorisation of adverse drug reactions based on information from several clinical studies in which KIOVIG was used as investigational medicinal product. Safety information from clinical trials is deleted from section 4.8 of the SmPC for simplification. The Package Leaflet is updated accordingly. The MAH took also the opportunity to implement QRD version 9.1 and to update the details of the local representative for Slovakia. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0720 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                | 16/07/2015 | n/a |

<div style=\"page-break-after: always\"></div>

| IAIN/0066   | - Change to importer, batch release and quality control testing of the FP - or addition of a manufacturer for importation and/or batch release - including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/06/2015   | 02/06/2016   | Annex II and PL   | B.II.b.2.c.1 arrangements Replacement responsible Not   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|---------------------------------------------------------|
| IAIN/0064/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 29/05/2015   | 02/06/2016   | Annex II and PL   |                                                         |
| WS/0683     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/03/2015   | n/a          |                   |                                                         |

<div style=\"page-break-after: always\"></div>

|                    | the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |    |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0062             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 13/03/2015 | 02/06/2016 | PL |                                   |
| WS/0670            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                               | 26/02/2015 | n/a        |    |                                   |
| PSUSA/1633/ 201405 | Periodic Safety Update EU Single assessment - human normal immunoglobulin (IgG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/01/2015 | n/a        |    | PRAC Recommendation - maintenance |
| WS/0585/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change in test procedure for AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting | 23/10/2014 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|                    | material/reagent/intermediate, if an alternative test procedure is already authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0056            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/06/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IAIN/0057          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/04/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/1633/ 201305 | Periodic Safety Update EU Single assessment - human normal immunoglobulin (IgG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/01/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0050/G          | This was an application for a group of variations. Update of section 4.8 of the SmPC and consequential update to section 4 of the PL to reflect the change of frequency of ADRs already included in the SmPC following an update of the clinical trial safety data pool. Stroke and myocardial infarction have also been included as new ADRs based on post-marketing spontaneous reporting; PL has been updated accordingly. Editorial changes have been made to section 4.2 of the SmPC.and paediatric statements have been included to sections 4.4, 4.5, 4.8, 4.9 and 5.1 of the SmPC as per previous commitments during variation IB/46. The PI is updated following the new QRD v.9. Finally the MAH proposed to | 24/10/2013 | 03/06/2014 | SmPC and PL | The MAH performed a pooled data analysis from 4 clinical trials (2 trials in PID patients and one trial in patients with ITP, part of the original MAA, and the one trial in subjects with MMN, assessed in a previous variation) and post- marketing spontaneous reports (including 2 reports of myocardial infarction and 2 of stroke) for a re-calculation of frequencies and frequency categories for a certain number of ADRs and to add Stroke and Myocardial Infarction in the Product Information (PI). As a result of the data analysis, frequencies and frequency categories have been changed for a few of the already reported ADRs in the PI, which was updated accordingly. Addition of stroke and myocardial infarction has been due to two reports of stroke and two reports of MI from post-marketing sources and the MAH has now incorporated them in the ADR list within frequency |

<div style=\"page-break-after: always\"></div>

|           | update the contact details of the Croatian, Portuguese and Romanian local representative. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                        |            |            |          | category 'unknown'. Relatedness and un-relatedness of ADRs to Kiovig treatment has been considered in the conservative approach described by the SmPC guideline. Furthermore, updates of the PI as for the results from previous procedures and the update to the current version of the QRD template have been introduced by the applicant.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0054 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                 | 27/06/2013 | 03/06/2014 | Annex II |                                                                                                                                                                                                                                                                                                                                                |
| II/0051/G | This was an application for a group of variations. This is an application for a group of variations related to the active substance manufacturing process. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation | 27/06/2013 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0053 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                 | 31/05/2013 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| II/0049   | Replacement of a test for the drug product for both: release testing/batch analysis as well as for future stability study testing. B.II.d.2.c - Change in test procedure for the finished product - Replacement of a biological/ immunological/immunochemical test method or a method using a biological reagent   | 25/04/2013   | n/a        |                        |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------|
| IAIN/0052 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                     | 12/04/2013   | n/a        |                        |           |
| II/0048   | Submission of the relevant validation data to demonstrate that the manufacturing process includes steps in accordance with the revision of the Ph. Eur. Monograph (01/2012: 0918). B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other                           | 21/02/2013   | n/a        |                        | variation |
| IB/0046   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                           | 03/08/2012   | 31/10/2012 | SmPC, Labelling and PL |           |
| IAIN/0047 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                | 07/06/2012   | n/a        |                        |           |

<div style=\"page-break-after: always\"></div>

|           | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0232   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of updated Certificate of Suitability B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 24/05/2012 | n/a        |             |                                                                                                                                                                     |
| IAIN/0045 | C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database                                                                                                                                                                                                                                                             | 10/05/2012 | n/a        |             |                                                                                                                                                                     |
| IB/0044   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                    | 25/04/2012 | n/a        |             |                                                                                                                                                                     |
| IA/0042   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                 | 08/11/2011 | n/a        |             |                                                                                                                                                                     |
| II/0040   | Update of section 4.4 of the SmPC to add a statement regarding hyperproteinemia and hyponatremia. Furthermore, changes are proposed                                                                                                                                                                                                                                            | 23/06/2011 | 27/07/2011 | SmPC and PL | Hyperproteinemia and increased serum viscosity may occur in patients receiving IGIV therapy. In addition, hyponatremia may occur in association with IVIG products. |

<div style=\"page-break-after: always\"></div>

|           | to align the SmPC with the revised Core SmPC for IVIg products. Minor editorial changes in section 4.2, 4.4 and 4.5 and PIL have been introduced. The list of local representatives is being updated in section 6 of the PIL. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            |                       | It is clinically critical to distinguish true hyponatremia from a pseudohyponatremia that is associated with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity and a possible predisposition to thromboembolic events.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0037   | Extension of indication to add the treatment of multifocal motor neuropathy (MMN) to the list of approved indications in 4.1. Consequential changes are made to section 4.2. The PIL is updated accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                            | 23/06/2011 | 27/07/2011 | SmPC, Annex II and PL | Please refer to the Scientific Discussion \"Kiovig/H/C/000628/II/37\" for further information.                                                                                                                                                                                                                                                                                                                     |
| II/0038   | Change in the manufacturing process of the active substance B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                     | 21/07/2011 | 21/07/2011 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0041/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                     | 01/06/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039 | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                                     | 12/05/2011 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0036  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/09/2010 | 06/12/2010 | SmPC, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit-risk balance, the CHMP is of the opinion that the quality, safety and efficacy of KIOVIG continues to be adequately and sufficiently demonstrated and therefore considered that the benefit-risk profile of KIOVIG continues to be favourable. The CHMP recommends the renewal of the Marketing Authorisation with unlimited validity. |
| II/0034 | Change of the manufacturing process of the active substance. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                       | 22/07/2010 | 05/08/2010 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0033/G   | This was an application for a group of variations. Changes to the finished product specifications. B.II.b.2.b.3 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and one of the test methods is a biol/immunol/immunochemical method B.II.d.2.z - Change in test procedure for the finished product - Other variation   | 22/07/2010   | 05/08/2010   |             |                                                                                                                                                                                                                                                                                                                                      |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028     | Update of SmPC section 4.6 with clinical safety information obtained since original licensure of the product in January 2006. The list of local representatives in the PIL has been updated. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                    | 20/05/2010   | 01/07/2010   | SmPC and PL | The MAH updated section 4.6 to include information on IGIV crossing the placenta during the third trimester. The proposed changes were supported by references to the published literature. The SPC changes provide an update of the safety information but do not affect the overall positive benefit-risk balance of this product. |
| II/0027     | Update of SmPC section 4.8 and PIL section 4 with clinical safety information obtained since original licensure of the product. Furthermore, section 4 \"Possible side effects\" of the Package Leaflet has been adapted to the QRD template. Update of Summary of Product Characteristics and Package Leaflet                                                                                                     | 20/05/2010   | 01/07/2010   | SmPC and PL | The MAH has proposed changes to section 4.8 of the SPC based on the evaluation of case reports received by the MAH in the post-marketing phase of Kiovig. The changes to the SPC and PIL provide an update of the safety information for Kiovig but do not affect the overall positive benefit-risk balance of this product.         |
| II/0026     | Update of the clinical safety information obtained since the original licensure of the product in January                                                                                                                                                                                                                                                                                                        | 20/05/2010   | 01/07/2010   | SmPC and PL | The SPC of Kiovig was updated to include more details to the warning statements in section 4.4, particularly with                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | 2006. SPC sections 4.2, 4.3, 4.4 and 4.9 are updated. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                          |            |            |                        | regard to transfusion related acute lung injury (TRALI), hemolysis and aseptic meningitis (ASM). Patients with cardiac impairment have been added as being at particular risk of adverse events in case of overdose (4.9). In addition, some minor changes have been introduced in sections 4.2 and 4.3. In support of the changes of the Kiovig SPC, which is based on the core SPC for human normal immunoglobulin for intravenous administration (IVIg) (CPMP/BPWG/859/95), the company has provided the updated CCSI as well as published literature.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035 | To include the PMF Annual Update B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 20/05/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0030 | To introduce a new vial size of 30g/300ml for Kiovig. New presentation(s)                                                                                                                                                                                                       | 18/02/2010 | 05/05/2010 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0031 | Change in the manufacturing process of the intermediate. Change(s) to the manufacturing process for the active substance                                                                                                                                                        | 18/02/2010 | 11/03/2010 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0029 | IB_36_a_Change in shape or dimensions of the container/closure - sterile ph. forms/biologicals                                                                                                                                                                                  | 26/01/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| II/0025   | To extend the room termperature storage of the final product from 9 to 12 months within the licensed shelf life of 24 months. This change affects the product information annexes I, IIIA and IIIB. At this occassion the MAH takes the oportunity to update the local representatives in the annex IIIB. Change(s) to shelf-life or storage conditions   | 17/12/2009   | 25/01/2010   | SmPC, Labelling and PL   |                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------|
| 2PMF/0032 | Inclusion of the updated or amended Plasma Master File (Baxter EMEA/H/PMF/000003/04) in the marketing authorisation dossier                                                                                                                                                                                                                               | 08/01/2010   | n/a          |                          |                 |
| IB/0024   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                                                                                                                                                        | 14/08/2009   | n/a          |                          |                 |
| IB/0023   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                                                                                                                                                        | 14/08/2009   | n/a          |                          |                 |
| IB/0022   | IB_31_b_Change to in-process tests/limits during manufacture - addition of new tests/limits                                                                                                                                                                                                                                                               | 14/08/2009   | n/a          |                          |                 |
| II/0021   | Use of a new method as the primary method for the determination of S/D reagents concentration in the finished product as well as in the in-process controls in the manufacturing process of the drug substance. The currently approved methods shall still be used as backup methods.                                                                     | 19/03/2009   | 23/03/2009   |                          | Quality changes |

<div style=\"page-break-after: always\"></div>

| II/0017   | Change(s) to the manufacturing process for the active substance                                                                                                                                                       | 24/07/2008   | 28/07/2008   |                                  |                                                                                                                                                                                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0011   | Quality changes                                                                                                                                                                                                       | 20/09/2007   | 28/07/2008   |                                  |                                                                                                                                                                                                                                  |
| MF/0020   | 2PMF (2nd step of PMF certification procedure)                                                                                                                                                                        | 26/06/2008   | n/a          |                                  |                                                                                                                                                                                                                                  |
| II/0019   | Change to the manufacturing process. Change(s) to the manufacturing process for the active substance                                                                                                                  | 30/05/2008   | 05/06/2008   |                                  |                                                                                                                                                                                                                                  |
| II/0018   | Introduction of a new test for determination of protein in the final product. The current approved one will be used as an alternative. Change(s) to the test method(s) and/or specifications for the finished product | 24/04/2008   | 28/04/2008   |                                  |                                                                                                                                                                                                                                  |
| IB/0016   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                    | 29/11/2007   | n/a          |                                  |                                                                                                                                                                                                                                  |
| II/0014   | Quality changes                                                                                                                                                                                                       | 15/11/2007   | 22/11/2007   |                                  |                                                                                                                                                                                                                                  |
| IB/0015   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                    | 26/10/2007   | n/a          |                                  |                                                                                                                                                                                                                                  |
| II/0013   | Update of Summary of Product Characteristics, Annex II, Labelling and Package Leaflet Update of the Product Information in compliance with                                                                            | 19/07/2007   | 21/08/2007   | SmPC, Annex II, Labelling and PL | The SPC, labelling and PL were updated in compliance with the QRD template version 7.2. In addition, an editorial error was corrected in Annex II and the list of local representatives in the PL was updated. The MAH committed |

<div style=\"page-break-after: always\"></div>

|         | the current QRD template version 7.2, editorial correction in the Annex II and update of the local representatives section in the Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                       |            |            |                        | to further review the section \"Possible side effects\" of the PL at the next available opportunity.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------|
| MF/0012 | 2PMF (2nd step of PMF certification procedure)                                                                                                                                                                                                                                       | 06/06/2007 | n/a        |                        |                                                                                                      |
| IB/0010 | IB_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                                                     | 06/03/2007 | n/a        |                        |                                                                                                      |
| IB/0009 | IB_31_b_Change to in-process tests/limits during manufacture - addition of new tests/limits                                                                                                                                                                                          | 27/02/2007 | n/a        |                        |                                                                                                      |
| II/0008 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                      | 24/01/2007 | 29/01/2007 |                        |                                                                                                      |
| II/0006 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                      | 16/11/2006 | 21/11/2006 |                        |                                                                                                      |
| IB/0007 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                                                                                   | 15/11/2006 | n/a        |                        |                                                                                                      |
| N/0005  | To update Annex III according to the newest QRD template for vial lable and outer carton and to add the EU Marketing Authosisation numbers. In Annex III B the phone number of the local representative for Germany and the adress of the Finnish local representative were updated. | 15/08/2006 | n/a        | SmPC, Labelling and PL |                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | Furthermore, minor lingustic and QRD changes were introduced in the Danish, German, Portuguese and Swedish Annexes Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   |            |            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| II/0003 | Change to the test procedure and/or specification of a raw material                                                                                                                                                   | 27/07/2006 | 03/08/2006 |
| MF/0004 | 2PMF (2nd step of PMF certification procedure)                                                                                                                                                                        | 19/06/2006 | n/a        |
| IB/0001 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                    | 02/05/2006 | n/a        |
| IA/0002 | IA_25_b_01_Change to comply with Ph. - compliance with EU Ph. update - active substance                                                                                                                               | 02/05/2006 | n/a        |